Home / Therapies / GLP-1 Agonist Therapy Center (page 9)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

GLP-1 Receptor Agonist a Treatment Option in Type 2 Patients with Renal Insufficiency

Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …

Read More »

New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?

Dulaglutide shows efficacy in diabetes patients with poor glycemic control already taking multiple oral medications…. Patients with uncontrolled diabetes already taking multiple oral agents often require insulin therapy for better glycemic control but insulin therapy is associated with hypoglycemia and weight gain. Dulaglutide, approved by the FDA in September 2014, …

Read More »

Two Positive Phase 3 Trials for ITCA 650, a GLP-1 Agonist, in Type 2 Diabetes

FREEDOM-1 and FREEDOM-1 High Baseline (HBL) study showed positive results when the continuous subcutaneous infusion of exenatide is added to standard oral diabetes medications….  ITCA 650 is a continuous subcutaneous infusion of exenatide through a pump for the treatment of type 2 diabetes. FREEDOM-1 is a double blinded, randomized, placebo-controlled, multicenter, phase …

Read More »

ADA 2014 – GLP-1 Update

For this month’s special feature we have a selection of the GLP-1 abstracts and releases from the recent American Diabetes Association’s 74th Scientific Sessions in San Francisco. New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes New Phase 3a findings show IDegLira, the …

Read More »